The Low-Fluence Q-Switched Nd:YAG Laser Treatment for Melasma: A Systematic Review.
Lee YS, Lee YJ, Lee JM, Han TY, Lee JH, Choi JE.
Medicina (Kaunas). 2022 Jul 14;58(7):936. doi: 10.3390/medicina58070936.
Update on Melasma-Part II: Treatment.
Cassiano DP, Espósito ACC, da Silva CN, Lima PB, Dias JAF, Hassun K, Miot LDB, Miot HA, Bagatin E.
Dermatol Ther (Heidelb). 2022 Sep;12(9):1989-2012. doi: 10.1007/s13555-022-00780-4. Epub 2022 Jul 29.
Melasma Treatment: An Evidence-Based Review.
McKesey J, Tovar-Garza A, Pandya AG.
Am J Clin Dermatol. 2020 Apr;21(2):173-225. doi: 10.1007/s40257-019-00488-w.
[Chemical peeling for treatment of Melasma, pigmentary disorders and hyperpigmentation : Indications, effectivity and risks].
Borelli C, Fischer S.
Hautarzt. 2020 Dec;71(12):950-959. doi: 10.1007/s00105-020-04712-1.
Glaucoma.
Dietze J, Blair K, Zeppieri M, Havens SJ.
2024 Mar 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
Disorders of hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentation.
Ko D, Wang RF, Ozog D, Lim HW, Mohammad TF.
J Am Acad Dermatol. 2023 Feb;88(2):291-320. doi: 10.1016/j.jaad.2021.12.065. Epub 2022 Feb 12.
Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring.
Avci P, Gupta A, Sadasivam M, Vecchio D, Pam Z, Pam N, Hamblin MR.
Semin Cutan Med Surg. 2013 Mar;32(1):41-52.
Optimizing Q-switched lasers for melasma and acquired dermal melanoses.
Aurangabadkar SJ.
Indian J Dermatol Venereol Leprol. 2019 Jan-Feb;85(1):10-17. doi: 10.4103/ijdvl.IJDVL_1086_16.
Post-Inflammatory Hypopigmentation: Review of the Etiology, Clinical Manifestations, and Treatment Options.
Rao M, Young K, Jackson-Cowan L, Kourosh A, Theodosakis N.
J Clin Med. 2023 Feb 3;12(3):1243. doi: 10.3390/jcm12031243.
Melasma: an Up-to-Date Comprehensive Review.
Ogbechie-Godec OA, Elbuluk N.
Dermatol Ther (Heidelb). 2017 Sep;7(3):305-318. doi: 10.1007/s13555-017-0194-1. Epub 2017 Jul 19.
